To avoid these possible confounding factors such as different tumor entities or treatment lines and different PD‐L1 expressions, in our work we used a clearly defined population with regard to the tumor entity NSCLC with high PD‐L1 expression of the tumor and evaluated the different therapy modalities with chemoimmunotherapy combination and monoimmunotherapy separately. This evidence concerns the gene CD274 and neoplasm.